PAVmed (NASDAQ:PAVM – Get Free Report) and Embecta (NASDAQ:EMBC – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.
Risk & Volatility
PAVmed has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Embecta has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.
Valuation & Earnings
This table compares PAVmed and Embecta”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PAVmed | $2.45 million | 3.45 | -$64.18 million | ($4.35) | -0.18 |
| Embecta | $1.12 billion | 1.00 | $78.30 million | $1.35 | 14.45 |
Insider and Institutional Ownership
19.9% of PAVmed shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 14.7% of PAVmed shares are held by company insiders. Comparatively, 0.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings for PAVmed and Embecta, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PAVmed | 0 | 0 | 1 | 1 | 3.50 |
| Embecta | 0 | 1 | 1 | 0 | 2.50 |
PAVmed currently has a consensus target price of $19.00, suggesting a potential upside of 2,384.96%. Embecta has a consensus target price of $23.00, suggesting a potential upside of 17.89%. Given PAVmed’s stronger consensus rating and higher probable upside, equities analysts clearly believe PAVmed is more favorable than Embecta.
Profitability
This table compares PAVmed and Embecta’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PAVmed | 602.97% | N/A | -92.36% |
| Embecta | 6.97% | -18.54% | 11.43% |
About PAVmed
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
About Embecta
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.
